SEARCH

SEARCH BY CITATION

References

  • Albin R. L. and Greenamyre J. T. (1992) Alternative excitotoxic hypothesis. Neurology 42, 733738.
  • Alexi T., Hughes P. E., Faull R. L. and Williams C. E. (1998) 3-nitropropionic acid’s lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 9, R57R64.
  • Beal M. F. (2004) Mitochondrial dysfunction and oxidative damage in Alzheimer’s and Parkinson’s diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 36, 381386.
  • Binienda Z. K. and Ali S. F. (2001) Neuroprotective role of L-carnitine in the 3-nitropropionic acid induced neurotoxicity. Toxicol. Lett. 125, 6773.
  • Binienda Z. K., Sadovova N. V., Rountree R. L., Scallet A. C. and Ali S. F. (2001) Effect of L-carnitine pretreatment on 3-nitropropionic acid-induced inhibition of rat brain succinate dehydrogenase activity. Ann. NY Acad. Sci. 939, 359365.
  • Binienda Z., Virmani A., Przybyla-Zawislak B. and Schmued L. (2004) Neuroprotective effect of L-carnitine in the 3-nitropropionic acid (3-NPA)-evoked neurotoxicity in rats. Neurosci. Lett. 367, 264267.
  • Borlongan C. V., Koutouzis T. K., Freeman T. B., Cahill D. W. and Sanberg P. R. (1995) Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington’s disease. Brain Res. 697, 254257.
  • Borlongan C. V., Nishino H. and Sanberg P. R. (1997) Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington’s disease: a speculative explanation. Neurosci. Res. 28, 185189.
  • Brouillet E., Condé F., Beal M. F. and Hantraye P. (1999) Replicating Huntington’s disease phenotype in experimental animals. Prog. Neurobiol. 59, 427468.
  • Brown J. C. III, Tse H., Skifter D. S., Christies J. M., Andaloro V. J., Kemp M. C., Watkins J. C., Jane D. E. and Monaghan D. T. (1998) [3H]Homoquinolinic acid binds to a subpopulation of NMDA receptors and to a novel binding site. J. Neurochem. 71, 14641470.
  • Cowan C. M. and Raymond L. A. (2006) Selective neuronal degeneration in Huntington’s disease. Curr. Top. Dev. Biol. 75, 2571.
  • Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689695.
  • De Carvalho L. P., Bochet P. and Rossier J. (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 28, 445452.
  • Del Rio P., Montiel T., Chagoya V. and Massieu L. (2007) Exacerbation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: relation to energy imbalance or ATP depletion? Neuroscience 146, 15611570.
  • Gadaleta M. N., Cormio A., Pesce V., Leza A. M. and Cantatore P. (1998) Aging and mitochondria. Biochimie 80, 863870.
  • Gülçin I. (2006) Antioxidant and antiradical activities of L-carnitine. Life Sci. 78, 803811.
  • Hagen T. M., Moreau R., Suh J. H. and Visioli F. (2002) Mitochondrial decay in the aging rat heart: evidence for improvement by dietary supplementation of acetyl-L-carnitine and/or lipoic acid. Ann. NY Acad. Sci. 85, 214223.
  • Herrera-Mundo M. N., Silva-Adaya D., Maldonado P. D., Galván-Arzate S., Andrés-Martínez L., Pérez-De La Cruz V., Pedraza-Chaverrí J. and Santamaría A. (2006) S-Allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction. Neurosci. Res. 56, 3944.
  • Jacquard C., Trioulier Y., Cosker F., Escartin C., Bizat N., Hantraye P., Cancela J. M., Bonvento G. and Brouillet E. (2006) Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J. 20, E245E259.
  • Jara-Prado A., Ortega-Vázquez A., Martínez-Ruano L., Rios C. and Santamaría A. (2003) Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox. Res. 5, 237244.
  • Lehmann P. A. (1980) Dosis letal o efectiva media: un cálculo manual fácil y rápido. Arch. Farmacol. Toxicol. (Madrid) 6, 161178.
  • Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787795.
  • Lowry O. H., Rosebrough N. J., Farr A. L. and Randal R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265275.
  • Nakamura K. and Animoff M. J. (2007) Huntington’s disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc.) 43, 97116.
  • Nalecz K. A. and Nalecz M. J. L. (1996) Carnitine – a known compound, a novel function in neuronal cells. Acta Neurobiol. Exp. 56, 597609.
  • Nicholls D. G., Johnson-Cadwell L., Vesce S., Jekabsons M. and Yadava N. (2007) Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J. Neurosci. Res. 85, 32063212.
  • Olney J. W., Adamo N. J. and Ratner A. (1971) Monosodium glutamate effects. Science 172, 294.
  • Paxinos G. and Watson C. (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
  • Pérez-De La Cruz V., González-Cortés C., Galván-Arzate S., Medina-Campos O. N., Pérez-Severiano F., Ali S. F., Pedraza-Chaverrí J. and Santamaría A. (2005) Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington’s disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience 135, 463474.
  • Pérez-De La Cruz V., González-Cortés C., Pedraza-Cheverrí J., Maldonado P. D., Andrés-Martínez L. and Santamaría A. (2006) Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res. Bull. 68, 379383.
  • Pérez-Severiano F., Rodríguez-Pérez M., Pedraza-Chaverrí J. et al. (2004) S-Allylcysteine, a garlic-derived antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage in rats. Neurochem. Int. 45, 11751183.
  • Picconi B., Barone I., Pisani A., Nicolai R., Benatti P., Bernardi G., Calvani M. and Calabresi P. (2006) Acetyl-L-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine. Neuropharmacology 50, 917923.
  • Ribeiro C. A., Grando V., Dutra-Filho C. S., Wannmacher C. M. and Wajner M. (2006) Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J. Neurochem. 99, 15311542.
  • Rodríguez E., Méndez-Armenta M., Villeda-Hernández J., Galván-Arzate S., Barroso-Moguel R., Rodríguez F., Ríos C. and Santamaría A. (1999) Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology 139, 111118.
  • Rodríguez-Martínez E., Camacho A., Maldonado P. D., Pedraza-Chaverrí J., Santamaría D., Galván-Arzate S. and Santamaría A. (2000) Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 858, 436439.
  • Santamaría A. and Jiménez M. E. (2005) Oxidative/nitrosative stress, a common factor in different neurotoxic paradigms: an overview. Curr. Top. Neurochem. 4, 120.
  • Santamaría A., Galván-Arzate S., Lisý V., Ali S. F., Duhart H. M., Osorio-Rico L., Ríos C. and Stástný F. (2001) Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 12, 871874.
  • Santamaría A., Salvatierra-Sánchez R., Vázquez-Román B., Santiago-López D., Villeda-Hernández J., Galván-Arzate S., Jiménez-Capdeville M. E. and Ali S. F. (2003) Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J. Neurochem. 86, 479488.
  • Sas K., Robotka H., Toldi J. and Vécsei L. (2007) Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257, 221239.
  • Schwarcz R., Scholz D. and Coyle J. T. (1978) Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. Neuropharmacology 17, 145151.
  • Shear D. A., Dong J., Gundy C. D., Haik-Creguer K. L. and Dunbar G. L. (1998) Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 12171240.
  • Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309379.
  • Stumpf D. A., Parker D. and Angelini C. (1985) Carnitine deficiency, organic acidemias and Reyes syndrome. Neurology 35, 10411045.
  • Tunez I., Montilla P., Del Carmen-Muñoz M., Feijoo M. and Salcedo M. (2004) Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J. Pineal Res. 37, 252256.
  • Tunez I., Muñoz M. C. and Montilla P. (2005) Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 74, 113118.
  • Tunez I., Drucker-Colin R., Jimena I., Medina F. J., Del Carmen-Muñoz M., Pena J. and Montilla P. (2006) Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington’s disease. J. Neurochem. 97, 619630.
  • Virmani A. and Binienda Z. (2004) Role of carnitine esters in brain neuropathology. Mol. Aspects Med. 25, 533549.
  • Wang C., Sadovova N., Ali H. K. et al. (2007) L-Carnitine protects neurons from 1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture. Neuroscience 144, 4655.
  • Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A., Cai J., Peng T. I., Jones D. P. and Wang X. (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 11291132.
  • Zaleska M. A. and Floyd R. A. (1985) Regional lipid peroxidation in rat brain in vivo: possible role of endogenous iron. Neurochem. Res. 10, 397410.
  • Zeevalk G. D., Derr-Yellin E. and Nicklas W. J. (1995) Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. J. Pharmacol. Exp. Ther. 275, 11241130.